Oral Chitomur versus capsule placebo in men with benign prostatic hyperplasia
Randomized study in people · 2013
- What was studied
- 50 men aged 62–83 with benign prostatic hyperplasia. Chitomur 30, capsule placebo 20.
- Main finding
- Post-course peak urinary flow was 12.7 vs 9.4 mL/s and prostate symptom scores were 13.2 vs 15.6 with Chitomur versus placebo. Prostate volume showed no significant change.
Chitomur versus placebo. One month later, 10.36 vs 8.3 mL/s. · Table 1 marks p < 0.001 versus placebo at the post-course visit only.
Reported findings and study design
Chitomur 30 versus capsule placebo 20. Uroflowmetry, post-void residual volume, prostate ultrasound, and IPSS and quality-of-life questionnaires.
Population or model 50 men aged 62–83 with benign prostatic hyperplasia. Chitomur 30, capsule placebo 20.
Dose, route and schedule
Two 10 mg capsules twice daily with meals for 15 days (40 mg/day as reported). The comparator received placebo capsules. Methods place the post-course visit on day 16. The results narrative also uses day 14.
Protocol source ↗ · Russian full-article reproduction, methods and Tables 1–2. Indexed citation and abstract cross-checked. The indexed second-author initials differ from the reproduction.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Peak urinary flow · post-course | 12.7 vs 9.4 mL/s | Chitomur versus placebo. One month later, 10.36 vs 8.3 mL/s. · Table 1 marks p < 0.001 versus placebo at the post-course visit only. |
| Post-void residual urine · post-course | 23.2 vs 72.1 mL | One month later, 48.7 vs 69.8 mL. · Table 1 marks p < 0.001 versus placebo at both times. |
| International Prostate Symptom Score · post-course | 13.2 vs 15.6 points | One month later, 15.7 vs 17.9. The table gives a single 17.4-point baseline. · Table 2 marks p < 0.001 versus placebo at the post-course visit only. |
| Prostate volume and mean flow | No significant prostate-volume change | The table gives no significance marker for mean urinary flow. |
| Adverse events | None reported among Chitomur recipients | The paper gives no systematic harms table. |
Tables 1–2 · urinary measures by visit
| Measure | Single baseline column | Chitomur post-course | Placebo post-course | Chitomur one month later | Placebo one month later |
|---|---|---|---|---|---|
| Peak flow (mL/s) | 8.9 ± 0.8 | 12.7 ± 0.8 | 9.4 ± 1.4 | 10.36 ± 0.9 | 8.3 ± 1.7 |
| Mean flow (mL/s) | 4.1 ± 0.7 | 4.7 ± 1.3 | 4.2 ± 1.6 | 4.4 ± 1.5 | 3.9 ± 1.7 |
| Residual urine (mL) | 77.4 ± 16.1 | 23.2 ± 8.9 | 72.1 ± 19.2 | 48.7 ± 10.5 | 69.8 ± 13.7 |
| IPSS | 17.4 ± 0.9 | 13.2 ± 1.2 | 15.6 ± 2.2 | 15.7 ± 1.1 | 17.9 ± 3.1 |
| Quality-of-life index | 3.3 ± 0.2 | 2.4 ± 0.3 | 2.9 ± 0.5 | 2.8 ± 0.3 | 3.2 ± 0.6 |
Printed means and ± terms. The report gives one baseline column and inconsistent post-course timing. Peak flow and IPSS moved back toward baseline at follow-up.
The small study reported differences in urinary symptoms and function; prostate size did not measurably change. The conflict about masking limits confidence.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- Methods describe a blinded randomized study and the conclusion calls it open. The accessible report does not explain concealment, masking or placebo contents.
- Tables use a single baseline column and the reported endpoint timing varies. The sample and follow-up are too limited to characterize uncommon harms.
Source details
Journal article — commercial reproduction
Russian full-article reproduction, methods and Tables 1–2. Indexed citation and abstract cross-checked. The indexed second-author initials differ from the reproduction.
Methods and numerical tables checked
Sources checked
Citation
V. G. Gomberg, A. P. Ryzhak, R. V. Lyutov. Oral Chitomur versus capsule placebo in men with benign prostatic hyperplasia Advances in Gerontology / Uspekhi Gerontologii. 2013;26(3):476–480. PMID 24640697.